Brokerages Set Victrex plc (LON:VCT) PT at GBX 2,182.50

Victrex plc (LON:VCT) has received an average rating of “Hold” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is GBX 2,182.50 ($28.52).

Several equities analysts have recently commented on VCT shares. Credit Suisse Group reaffirmed an “outperform” rating on shares of Victrex in a report on Tuesday, November 12th. UBS Group reaffirmed a “neutral” rating on shares of Victrex in a report on Monday, November 11th. Liberum Capital reaffirmed a “buy” rating on shares of Victrex in a report on Monday, October 7th. Peel Hunt reaffirmed a “hold” rating on shares of Victrex in a report on Monday, September 16th. Finally, Stifel Nicolaus lowered Victrex to a “hold” rating and lowered their target price for the company from GBX 2,255 ($29.47) to GBX 2,125 ($27.77) in a report on Friday, September 27th.

LON VCT traded up GBX 8 ($0.10) on Thursday, hitting GBX 2,356 ($30.79). 137,154 shares of the stock traded hands, compared to its average volume of 274,177. The stock has a 50-day moving average of GBX 2,183.24 and a 200 day moving average of GBX 2,113.49. Victrex has a twelve month low of GBX 1,813.68 ($23.70) and a twelve month high of GBX 2,720 ($35.54). The company has a market capitalization of $2.05 billion and a P/E ratio of 20.49.

About Victrex

Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.

Featured Article: Depreciation

Analyst Recommendations for Victrex (LON:VCT)

Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.